• 1. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 2. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 3. Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  Matthew J. Gaunt,Jinquan Yu,Jonathan B. Spencer Chem. Commun., 2001, 1844-1845
• 4. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 5. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isocoumarans Isocoumarans
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isocoumarans

Professional Introduction to 6-Bromo-1,3-dihydroisobenzofuran-1-ol (CAS No. 100655-92-3)

6-Bromo-1,3-dihydroisobenzofuran-1-ol, identified by the Chemical Abstracts Service Number (CAS No.) 100655-92-3, is a significant compound in the realm of pharmaceutical chemistry and medicinal research. This heterocyclic brominated alcohol belongs to the dihydroisobenzofuran class, a structural motif widely recognized for its biological activity and synthetic utility. The presence of a bromine substituent at the 6-position enhances its reactivity, making it a valuable intermediate in the synthesis of more complex molecules, particularly in drug discovery programs.

The compound's structure, featuring a fused benzene ring with an additional hydroxyl group at the 1-position, contributes to its versatility in medicinal chemistry. The dihydroisobenzofuran scaffold is known to exhibit various pharmacological properties, including anti-inflammatory, antimicrobial, and anticancer effects. These attributes have prompted extensive research into derivatives of this core structure, with 6-Bromo-1,3-dihydroisobenzofuran-1-ol serving as a key precursor in many synthetic pathways.

In recent years, advancements in computational chemistry and high-throughput screening have accelerated the identification of novel bioactive compounds. The brominated dihydroisobenzofuran derivative has been subjected to rigorous computational modeling to predict its interactions with biological targets. Studies suggest that its molecular framework can modulate enzyme activity and receptor binding, particularly in pathways associated with neurodegenerative diseases and cancer metabolism. This has spurred interest among researchers aiming to develop next-generation therapeutics.

The synthesis of 6-Bromo-1,3-dihydroisobenzofuran-1-ol typically involves multi-step organic transformations, often starting from readily available aromatic precursors. The introduction of the bromine atom at the 6-position is commonly achieved through electrophilic aromatic substitution reactions or metal-catalyzed cross-coupling processes. The hydroxyl group at the 1-position can be further functionalized via oxidation or reduction strategies, enabling the construction of diverse pharmacophores.

One of the most compelling applications of this compound lies in its role as a building block for kinase inhibitors. Kinases are enzymes central to numerous cellular processes, and their dysregulation is implicated in various diseases. By modifying the dihydroisobenzofuran core, chemists have generated libraries of compounds designed to selectively inhibit specific kinases. Preliminary data indicate that derivatives of 6-Bromo-1,3-dihydroisobenzofuran-1-ol exhibit promising inhibitory activity against certain cancer-related kinases, warranting further investigation.

The compound's potential extends beyond oncology; it has also been explored as a scaffold for antimicrobial agents. The structural features of dihydroisobenzofurans are known to disrupt bacterial cell membranes and inhibit vital metabolic pathways. Researchers have synthesized analogs of 6-Bromo-1,3-dihydroisobenzofuran-1-ol and evaluated their efficacy against resistant bacterial strains. Some derivatives have shown notable activity against Gram-negative pathogens, highlighting the compound's therapeutic promise.

In conclusion, 6-Bromo-1,3-dihydroisobenzofuran-1-ol (CAS No. 100655-92-3) represents a cornerstone in modern medicinal chemistry. Its unique structural features and reactivity make it an indispensable tool for synthesizing bioactive molecules with potential applications across multiple therapeutic areas. As research continues to uncover new derivatives and applications, this compound will undoubtedly remain at the forefront of pharmaceutical innovation.

• 4141-19-9(cis-1,3-O-Benzylideneglycerol)
• 2568-25-4(Benzaldehyde Propylene Glycol Acetal)
• 66222-24-0(Acetaldehyde benzyl ethylacetal)
• 127657-97-0([(2,2-dimethoxyethoxy)methyl]benzene)
• 1125-88-8(Benzaldehyde dimethyl acetal)
• 1663-61-2(Triethyl Orthobenzoate)
• 496-14-0(Phthalan)
• 42783-78-8(((2,2-Diethoxyethoxy)methyl)benzene)
• 142169-23-1(2,4-Benzodioxepin,3-ethenyl-1,5-dihydro-)
• 150990-60-6(3-(Diethoxymethyl)benzaldehyde)